DAY (DAY)

Docebo (NASDAQ:DCBO) is expanding its enterprise focus into government, healthcare, and artificial intelligence, as highlighted by CFO Brandon Farber at the Oppenheimer Technology Conference. The company is investing in these new verticals and leveraging its 365Talents acquisition to enhance its skills-management offering, aiming for improved ARR growth and a 20% EBITDA margin in 2026. Docebo also plans to introduce new AI tools like Knowledge Search and AgentHub to further differentiate its platform.

Docebo is experiencing accelerated growth driven by larger enterprise contracts, a stronger pipeline, and improving international performance, with core annual recurring revenue (ARR) increasing by 13.9%. The company is expanding its platform through the acquisition of 365Talents and the upcoming launch of new AI products, Enterprise Knowledge and AgentHub, in October. Docebo plans to invest in a dedicated healthcare business, pursue annual EBITDA-margin expansion, and launch a $70 million issuer bid, while focusing on integrating recent acquisitions rather than seeking new deals.

This article provides a collection of recent news headlines related to Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP). Key updates include Q2 2026 earnings highlights, the launch and sales performance of their fibromyalgia drug Tonmya, FDA interactions for a Lyme disease prevention drug, and various stock movements driven by regulatory approvals, buybacks, and financial filings. The news spans from June 2025 to August 2026, offering a timeline of significant events for the company.

Roper Technologies' subsidiary Illumia has appointed Eric Schuster as Chief Product Officer, signaling a stronger focus on AI and client-centric solutions. Schuster's background in AI and enterprise software is expected to enhance Illumia's product roadmap and contribute to Roper's strategy of investing in AI-driven vertical market SaaS. This move reinforces Roper's commitment to building experienced AI leadership within its portfolio companies to support its AI thesis, despite existing competitive and integration risks.

The article focuses on Paylocity Holding's NYSE-listed shares, emphasizing its subscription-driven human capital management (HCM) and payroll platform. It details how the company generates growth through its SaaS model, targeting mid-sized U.S. employers, and discusses the competitive landscape. The piece highlights that investors are evaluating the company's underlying fundamentals, given the quiet news environment and lack of fresh filings or analyst rating changes.